Issa et al. reported updated results from the AUGMENT-101 phase 1 trial in 68 patients with heavily pretreated (median 4 lines) R/R AML who received the menin inhibitor SNDX-5613 (now known as revumenib) with dose escalation [9]. This evidence concerns the gene MEN1 and acute myeloid leukemia.